Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-01

Study Completion Date

2023-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Individuals with cirrhosis are likely to develop overt hepatic encephalopathy for which diagnostic modalities and treatment options are limited. The purpose of this study is to determine if individuals with cirrhosis who experience hepatic encephalopathy would benefit from investigational microbiota restoration therapy due to their inherent cognitive alterations. Analysis for a correlation between changes in microbiome composition and specific blood biomarkers could allow for earlier diagnosis of HE which could then be treated earlier and with novel treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581

Hepatic Encephalopathy Cirrhosis

COMPLETED PHASE4

Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy

NCT05229289

Hepatic Encephalopathy

UNKNOWN NA

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204

Diabetes Complications Fatty Liver

TERMINATED PHASE2

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

NCT03712280

Hepatic Cirrhosis Hepatic Encephalopathy (HE)

COMPLETED PHASE2

Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy

NCT02019784

Liver Cirrhosis Hepatoencephalopathy, Early Fatal Progressive

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators hypothesize that changes in an individual's cognition due to HE-related liver cirrhosis can be stabilized and/or improved through investigational microbiota restoration therapeutic treatment. The main objective of this study is to determine if investigational microbiota restoration therapeutic treatment alters the cognitive function in individuals with cirrhosis who have been previously diagnosed with overt hepatic encephalopathy (HE). Once individuals have one HE episode, they are more likely to experience additional episodes, even after complying with standard of care. The number of HE episodes each study group experiences during the post-treatment follow-up will be compared among treatment groups. It is also anticipated that cognitive improvement will correlate with specific changes in the intestinal microbiota composition of these individuals likely shifting their microbiome away from baseline samples and becoming more like donor samples. Novel blood biomarkers potentially related to episodes of HE will be assessed in individuals before and after treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Encephalopathy Cirrhosis, Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Study individuals will be placed into one of four study treatment groups: High dose investigational microbiota restoration therapeutic RBX7455 group, Low dose investigational microbiota restoration therapeutic RBX7455 group, or a pill quantity-matched Placebo group. Individuals will be randomized in a 1:1:1/2:1/2 manner. It is anticipated of the 75 potentially enrolled individuals, 50 will receive active treatment (high or low dose investigational microbiota restoration therapeutic) and 25 will receive placebo.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

This is a double-blinded study meaning both Ochsner study staff and participating individuals will not know to which group they are assigned/randomized. A third party will be responsible for providing study participant randomization and recording the exact treatment to which all study participants are assigned.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High dose

Capsules of active drug will be supplied in 8-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.

Group Type EXPERIMENTAL

RBX7455

Intervention Type BIOLOGICAL

RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.

Low dose

Capsules of active drug will be supplied in 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.

Group Type EXPERIMENTAL

RBX7455

Intervention Type BIOLOGICAL

RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.

pill quantity-matched Placebo

Capsules of inactive compound will be supplied in 8- or 4-capsule blister packets to be taken twice per week for four weeks. Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Capsule with cellulose filler

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RBX7455

RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.

Intervention Type BIOLOGICAL

Placebo

Capsule with cellulose filler

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Microbiota Restoration Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Individuals who are male or female and are between the ages of 18 and 70 years.
2. Individuals with a current diagnosis of liver cirrhosis as evidenced by one or more of the following:

a. Liver Biopsy

OR a clinical suspicion of cirrhosis based on the presence of one or more of the following criteria:
1. Radiologic evidence of varices, cirrhosis or portal hypertension
2. Laboratory evidence of platelet count \<100,000 or AST/ALT ratio \>1
3. Endoscopic evidence of varices or portal gastropathy
4. Elastography (i.e. Fibroscan)
3. Individuals must have at least one previously documented episode of HE.
4. Individuals must be able to read and write in the English language.
5. Individuals must be able and willing to utilize the electronic device necessary to measure cognitive function without assistance from outside individuals once the training phase has been completed.
6. Individuals must be able to provide valid informed consent prior to any study related procedures.

Exclusion Criteria

1. Individuals who are color-blind.
2. Individuals actively using psychotropic substances including alcohol.
3. Individuals who are pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. Study individuals are expected to attest to this fact during their participation time. Females who are not surgically sterile or having undergone greater than one year of menopause will receive urine pregnancy tests at screening and initial drug dosing.
4. Presence of TIPS (transjugular intrahepatic portosystemic shunt).
5. Individuals with an active bacterial infection and are taking antibiotics for those infections at time of consent.
6. Individuals with ANC \<800 (neutropenia).
7. Individuals with MELD \>17.
8. Individuals with platelet count \<35,000/mm3.
9. Individuals who are immunocompromised due any of the following reasons:

1. HIV infection (CD4 count \<200/mm3) or AIDS diagnosis
2. Inherited/primary immunodeficiency disorders
3. Treatment with any anti-neoplastic agent within the last 3 months (excluding locoregional therapy for hepatocellular carcinoma)
4. Treatment with any immunosuppressant medications \[including but not limited to monoclonal antibodies to B cells or T cells, anti-TNF agents, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine), calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil\] within the last 3 months
10. Individuals who have previously undergone FMT.
11. Individuals with a history of colorectal cancer (all stages).
12. Individuals with a history of chronic intrinsic GI diseases such as inflammatory bowel disease (ulcerative colitis, Crohn's disease or microscopic colitis), eosinophilic gastroenteritis, celiac disease or irritable bowel syndrome as determined by Rome III criteria.
13. Individuals with a history of colectomy, major gastro-intestinal surgery, or intra-abdominal surgery.
14. Individuals with a history of Clostridium difficile infection six months prior to study enrollment.
15. Individuals with a history of chronic diarrhea.
16. Individuals currently participating in a research trial that involves drug or device intervention.
17. Individuals who are unable to fulfill all study criteria.
18. Individuals that the PI determines are not capable of participating in the research study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No